ClinicalTrials.gg
TerminatedNCT07216885Updated Oct 1, 2026

Solv Multi-Pass Hemodialysis System In-Center Clinical Study

An interventional study of Solv Multi-Pass Hemodialysis System in End Stage Renal Disease, sponsored by Mozarc Medical US LLC. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Mozarc Medical US LLC · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Due to funding the study has been stopped. All subjects enrolled have completed the follow-up and have exited the study.
Updated Oct 1, 2026Now TerminatedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
603rd of 638
4 · median 48
Started
2026
with 21 others
No phase
287 of 765
28 open now
Registered
746th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 603rd largest by enrollment of the 638 interventional ones that give a count, is one of 22 that started in 2026, is one of 287 with no phase, and was the 746th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

Solv In-Center clinical study is a pre-market, prospective, multicenter, single arm, open-label clinical study. The patient population will include patients with kidney failure or insufficiency requiring hemodialysis and/or ultrafiltration. Eligibility will be open to incident dialysis patients and patients currently receiving HD in an in-center environment. All vascular access types including AV-fistula, AV-graft, and tunneled hemodialysis catheters.

03

Conditions studied

  • End Stage Renal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects able and willing to give and interested to participate in the study
  • Subject aged 18 years or older
  • Subjects meets one of the following three conditions:

    • End stage renal disease (ESRD) patients who have been adequately treated with maintenance HD and deemed stable, according to the investigator, for at least three months
    • Incident end stage renal disease (ESRD) patients who have been prescribed HD therapy
    • Subjects on peritoneal dialysis who require conversion to hemodialysis, according to the investigator
  • Subjects who have adequate access, capable of providing a blood flow rate of at least 300 mL/min
  • Subject understands the nature of the procedures and the requirements of the study protocol
  • Subject is willing and able to comply with the protocol requirements and return to the treatment center for all required treatments and clinical evaluations

Exclusion criteria

Exclusion Criteria:

  • Subjects with baseline dry weight of ≤ 60 kg or ≥ 110 kg
  • Subjects with a documented history of non-compliance to scheduled hemodialysis sessions or clinic visits
  • Subjects who are pre-scheduled for a living kidney transplant within the next two months, who plan a change to peritoneal dialysis (PD) within the next two months or who require single needle dialysis therapy
  • Subjects with unstable electrolytes or acid base balance, in the opinion of the investigator
  • Subjects with any major surgery or major adverse cardiac event within 3 months of screening
  • Subjects with hemodynamic instability, defined as repeated hypo/hypertension, in the past 30 days from screening
  • Subjects with active or ongoing infection, in the opinion of the Investigator
  • Subjects with known , C or infection
  • Subject with documented coagulation disorders, active or bleeding risk or who is intolerant to heparin
  • Subjects who are currently participating or have previously participated in another interventional clinical trial in the past 4 weeks from screening
  • Subjects with any comorbidities possibly conflicting with the study purpose or procedures, in the opinion of the Investigator
  • Subjects who are pregnant or lactating or any patient with a who refuses to use medically acceptable means of
  • Subjects with an active, malignant disease and whose is \< 6 months, in the opinion of the investigator
  • Subjects with a \< 9 gm/dl in the past 30 days from screening
  • Subjects with significant intradialytic hypotension in 30 days from screening
  • Subjects with shock within 30 days from screening
  • Subjects with active seizures in the last 6 months from screening
  • Subjects with history of hemolytic anemia or thrombocytopenia
  • Subjects with vascular access dysfunction (switching ports (reverse lines or catheter replacement) in 30 days prior to screening, multiple tPA (tissue plasminogen activator) administrations) or patient who has had a thrombectomy procedure within 30 days prior to screening
  • Subjects with a documented history of congestive heart failure with symptoms consistent with Class III or IV, according to the investigator, or documented severe left ventricular dysfunction
  • Subjects with fluid overload due to intractable ascites secondary to liver cirrhosis
  • Subjects with active, life-threatening rheumatologic disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Solv Multi-Pass Hemodialysis System In-Center Subjects

    All subjects enrolled in the study and treated with the Solv Multi-Pass Hemodialysis System

    Device: Solv Multi-Pass Hemodialysis System

Interventions

  • DeviceSolv Multi-Pass Hemodialysis System

    Solv Multi-Pass Hemodialysis System

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint

    Evaluate the number of serious device-related adverse events that occur during the In-Center Phase of the study, to confirm there are no additional risks associated with the Solv System implementation of sorbent-based HD.

    Time frame: through study completion, an average of 1 year

  2. Primary Performance Endpoint

    Evaluate the mean single pool (sp)Kt/V for subjects undergoing conventional In-Center HD with the Solv Multi-Pass Hemodialysis System during the eight-week study Phase.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Serious adverse events and all device and/or therapy related adverse events

    Quantify all serious adverse events and all device and/or therapy related adverse events which occur during the Run-in and In-Center Phase, regardless of relationship to the Solv Multi-Pass Hemodialysis System or seriousness

    Time frame: through study completion, an average of 1 year

  2. Uremic toxin profile

    Characterize uremic toxin profile of urea, β-2 microglobulin and myoglobin

    Time frame: through study completion, an average of 1 year

  3. Electrolyte balance and evaluate mineral metabolism

    Verify electrolyte balance and evaluate mineral metabolism by characterizing pre-post session sodium, chloride, potassium, calcium, magnesium, bicarbonate, phosphate and glucose

    Time frame: through study completion, an average of 1 year

  4. Nutritional status

    Evaluate nutritional status by characterizing pre-post session albumin and change in body mass index (BMI)

    Time frame: through study completion, an average of 1 year

  5. Inflammation markers

    Assess inflammation markers by characterizing pre-session values of C-reactive protein (CRP)

    Time frame: through study completion, an average of 1 year

  6. Volume of UF removed

    Confirm that the volume of UF removed as indicated by the Solv System will be within 10% of target UF volume entered into the device per session, accounting for prescribed estimated dry weight, treatment time, and rinse back volume

    Time frame: through study completion, an average of 1 year

  7. Use of intradialytic medications

    Summarize the use of intradialytic anticoagulants and erythropoietin, phosphate binders and iron doses

    Time frame: through study completion, an average of 1 year

  8. Patient-reported outcome measures with KDQOL-36

    Quantify patient-reported outcome measures on KDQOL-36 questionnaire to assess patient quality of life and satisfaction, along with physicial and mental health. The KDQOL will be collected at baseline and IC- weeks 1, 4, and 8 for comparison

    Time frame: through study completion, an average of 1 year

  9. Patient-reported outcome measures with Dialysis Recovery Time Questionnaire

    Quantify patient-reported outcome measures on dialysis recovery time to assess amoujnt of time it takes for each subject to recover from a dialysis session. The DRT questionnaire will be collected at baseline and In-Center Weeks 1, 4, \& 8 for comparison.

    Time frame: through study completion, an average of 1 year

  10. User Experience with Solv

    Characterize the user experience via questionnaire (e.g., Solv set-up, recharging process, alarm management). The questionnaire will be provided to a sampling of users.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Carolina Nephrology
    Greenville, South Carolina 29605, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Sep 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Oct 15, 2025
StartActual
Jan 13, 2026
Primary completionActual
Sep 11, 2026
CompletionActual
Sep 11, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated
changed Oct 1, 2026
Enrollment
46 (estimated)→4 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Suspended→Terminated
    Enrollment 46 (estimated)→4 (actual)
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07216885
Lead sponsor
Mozarc Medical US LLC
Responsible party
Sponsor
First posted
Oct 15, 2025
Start date
Jan 13, 2026
Primary completion
Sep 11, 2026
Completion
Sep 11, 2026
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion